ARCH Venture Partners
- United States
- China
- United Kingdom
- Seed
- Series A
- Series B
- Life Sciences
- Biotechnology
ARCH Venture Partners champions audacious, science-driven entrepreneurship by investing in companies emerging from academic and national labs, particularly in biotech and strategic physical sciences like semiconductors. Since 1986, it has taken a long-term, contrarian stance, favoring imaginative, transformative technology ventures rather than short-term trends and helps them mature through sustained support.
Investment Thesis
Manager's Experience
Team
Robert Nelsen – Co-founder & Managing Director
Keith Crandell – Co-founder & Managing Director
Kristina Burow – Managing Director
Paul Berns – Managing Director
Clinton Bybee – Co-founder & Managing Director
Portfolio
908 Devices
Accompany Health
Aera Therapeutics
Agios Pharmaceuticals
AIRNA
Akamis Bio
Aledade
Alnylam Pharmaceuticals
Altos Labs
Arbor Biotechnologies
Areteia Therapeutics
Arsenal Biosciences
Aspen Neuroscience
Autobahn Therapeutics
Basking Biosciences
BE Biopharma
Beam Therapeutics
Bit Bio
Bitterroot Bio
Boundless Bio
Brii Biosciences
Carrick Therapeutics
City Therapeutics
CStone Pharmaceuticals
Curie Bio
Cytrellis Biosystems
Denali Therapeutics
Dewpoint Therapeutics
Dispatch Biotherapeutics
eGenesis
Elephas Biosciences
Encoded Therapeutics
Encodia
Enumerix
EQRx (Acquired)
Erasca